**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Heathwe Landau, Memorial Sloan Kettering, New York, New York.

**Main Body of the Abstract**
The unprecedented efficacy of BCMA-directed CAR T-cell therapies for heavily pre-treated Multiple Myeloma has led to the FDA-approval of two products.  Patients with light chain (AL) amyloidosis were not included in these trials due to safety concerns.  Yet, patients with AL failing initial treatment with daratumumab, bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) have limited treatment options, especially with advanced cardiac disease.  Here we detail the case of a patient with Mayo stage IIIA AL, who was safely and effectively treated with BCMA CAR-T cells.
A 52-year-old male was diagnosed with AL amyloidosis (3/2023) after 18 months of dyspnea and worsening exercise tolerance. Treatment course is summarized in Figure 1. He was treated on trial with Dara-VCd +/- CAEL-101 (NCT04512235) (3/2023) and achieved a partial response (PR) followed by progression. Treatment changed to Dara-lenalidomide-d (6/2023) but intolerance prompted switch to Dara-pomalidomide-d.  For < PR, cyclophosphamide was added.  Suboptimal response and clinical progression led to consideration of BCMA CAR T therapy.  Following lymphodepletion, he received ciltacabtagene autoleucel (12/2023). Grade 1 cytokine release syndrome (CRS) and pseudomonas bacteremia co-occurred on Day 6-7 and were managed with tociluzimab and cefepime, respectively.  By day 11 he was afebrile, hemodynamically stable and was discharged.  Day 28 restaging indicated minimal residual disease negative complete response.
This case represents the limitations of available therapies for patients with AL and advanced cardiomyopathy who are not candidates for high dose melphalan or carfilzomib.  BCMA-directed CAR T-cells were safely administered, led to rapid hematologic response and are worthy of further study.



  The Safety and Efficacy of Ciltacabtagene Autoleucel in Refractory Mayo stage IIIA AL Amyloidosis: A Case Report.PA164 (#437)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.